GDUFA III Talks Completed; Fees will Fund Inspection, Complex Generic Improvements
Executive Summary
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.
You may also be interested in...
COVID-19 Supplement Approvals Jump, Some On-Time Decision Rates Slip For US FDA
In FY '21 third quarter, on-time decision rate improved for generics and biosimilars, but dropped again for new drug applications.
PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals
Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.
US GDUFA III Talks In Final Stages, Agreement Nearly Complete
Final commitment letter preparations now under way as revenue issues are resolved.